News

NCCN releases new guidelines for cancer patients


 

NCCN Guidelines for Patients®:

Nausea and Vomiting

©NCCN® 2016

The National Comprehensive Cancer Network (NCCN) has released new educational materials designed to help cancer patients combat nausea and vomiting.

The NCCN Guidelines for Patients® for Nausea and Vomiting and NCCN Quick Guide™ for Nausea and Vomiting are the first patient resources from NCCN to focus specifically on supportive care.

The resources are available on NCCN.org/patients and via the NCCN Patient Guides for Cancer mobile app.

NCCN Guidelines for Patients are patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology. Each resource features guidance from US cancer centers designed to help people living with cancer talk with their physicians about the best treatment options for their disease.

NCCN Quick Guide™ sheets are 1-page summaries of key points in the patient guidelines. They include elements such as “questions to ask your doctor,” a glossary of terms, and medical illustrations of anatomy, tests, and treatments.

The NCCN Guidelines for Patients for Nausea and Vomiting:

  • Explain how these side effects are related to cancer treatment
  • List cancer treatments that can cause nausea and vomiting
  • Detail methods of preventing and treating these side effects
  • Outline methods of coping with nausea and vomiting
  • Provide a list of resources for information and support.

“At NCCN, our mission is to improve the lives of patients with cancer, and we are excited to be able to provide the information that will help patients better understand this common side effect of cancer treatment,” said Marcie R. Reeder, executive director of the NCCN Foundation.

“The NCCN Guidelines for Patients for Nausea and Vomiting are the first of a highly anticipated library of supportive care resources that provide patients with the same information their doctors use.”

Recommended Reading

Acute-onset hypokalemic paralysis with arsenic trioxide therapy in patient with acute promyelocytic leukemia
MDedge Hematology and Oncology
Decitabine elicits favorable response in high-risk AML/MDS
MDedge Hematology and Oncology
Ph-like ALL is highly prevalent in adults
MDedge Hematology and Oncology
Idelalisib held unlikely to become frontline therapy for CLL
MDedge Hematology and Oncology
CAR T-cell trial placed on hold again
MDedge Hematology and Oncology
FDA grants full approval for ponatinib
MDedge Hematology and Oncology
NICE recommends taking ibrutinib off CDF
MDedge Hematology and Oncology
Decitabine produces responses in high-risk MDS, AML
MDedge Hematology and Oncology
EC grants drug orphan status for AML, sarcoma
MDedge Hematology and Oncology
EC expands indication for arsenic trioxide in APL
MDedge Hematology and Oncology